From: The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe
Number | % of total patients | Rate/100 PYE (95% CI) | |
---|---|---|---|
QTC prolongation | 15 | 1.05 | 0.85 (0.48–1.41) |
Suicide attempts/Other overdoses | 7 | 0.49 | 0.40 (0.16–0.82) |
Heart Rate Anomaly | 4 | 0.28 | 0.23 (0.06–0.58) |
Convulsion | 4 | 0.28 | 0.23 (0.06–0.58) |
Overdose of sertindole | 4 | 0.28 | 0.23 (0.06–0.58) |
Syncope | 3 | 0.21 | 0.17 (0.04–0.50) |
Carcinoma/Tumour | 2 | 0.14 | 0.11 (0.01–0.41) |
Other serious adverse event | 48 | 3.35 | 2.73 (2.01–3.62) |
Total | 87 | 6.08 | 4.95 (3.96–6.10) |